Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
Status: Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 17 Apr 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 07 Dec 2017 Status changed from not yet recruiting to recruiting.